Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hakeem, L.
Right arrow Articles by Bhattacharyya, D. N.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

HIV-associated lipodystrophy - a new metabolic syndrome

Lukman Hakeem

Infectious Diseases Unit, Victoria Hospital, Kirkcaldy, Fife, Scotland, lukman.hakeem{at}faht.scot.nhs.uk

Ian W Campbell

Diabetic Centre, Victoria Hospital, Kirkcaldy, Fife, Scotland

Diptendu Nath Bhattacharyya

Infectious Diseases Unit, Victoria Hospital, Kirkcaldy, Fife, Scotland

Human immunodeficiency virus (HIV) associated lipodystrophy may affect up to half or even more HIV-infected patients receiving antiretroviral therapy. However, a simple practical definition for this condition is still lacking. Features of lipoatrophy and lipohypertrophy may be seen in this condition. Intrinsic host factors and disease status, as well as treatment duration and type, probably play key roles in the aetiology. Several metabolic abnormalities such as dyslipidaemia and insulin resistance have been commonly reported in these patients. Most attempts to improve or reverse abnormal fat distribution have so far only shown modest success. Therefore, choosing optimal antiretroviral therapy is vital. There are too few reasons to support widespread use of rosiglitazone and metformin in these patients except on an individual basis. However, lipid lowering agents should be considered in the treatment of severe hypertriglyceridaemia and elevated low-density lipoprotein-cholesterol or a combination of both as lipid abnormalities are commonly seen in thesepatients. Advances in plastic surgery are attractive treatment options as they give immediate results.

Key Words: antiretroviral therapy • human immunodeficiency virus lipodystrophy • metabolic syndrome.

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 3, 129-134 (2008)
DOI: 10.1177/14746514080080030401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
A. S Wierzbicki, S. D Purdon, T. C Hardman, R. Kulasegaram, and B. S Peters
Review: Clinical aspects of the management of HIV lipodystrophy
The British Journal of Diabetes & Vascular Disease, May 1, 2008; 8(3): 113 - 119.
[Abstract] [PDF]